A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Molecular Markers
August 2, 2017
This is an excellent summary of progress during the past year in all aspects of lung cancer, from prevention/detection through molecular therapies and future perspectives. Each section is written by a handful of international experts.
May 8, 2017
Researchers conducted a study, published in Nature, to investigate whether this genetic diversity could be tracked clinically.
September 27, 2016
The authors assessed the relationship between second hand smoke exposure in non-smokers and mortality related to lung cancer using serum cotinine levels. Cotinine levels were associated with survival, death from lung cancer, and death from all cancers after adjustment. Such levels identify second hand smoke effects.
May 5, 2016
This is an outstanding and provocative editorial comment concerning treatment costs of lung cancer based on an article published in the last issue of the European Respiratory Journal. It reveals discrepancies in access to new therapies based on therapeutic targets due to molecular testing and treatment costs.
August 22, 2015
This comprehensive review outlines changes in the WHO classification of lung tumors, chagnes that will affect our clinical practice in the near future.
May 19, 2015
Pts with suspected lung cancer underwent sampling of normal-appearingbronchial epithelial cells in the main bronchi, unrelated to the suspected tumor. Gene expression was analyzed and classified. Classification for cancer was about 75% accurate.
May 8, 2015
Targeting specific genetic changes in cancer cells offers patients personalized therapy for their tumors. The number of identified abnormalities is rapidly increasing, and determining whether they represent driver mutations or background noise is increasingly difficult. The IBM Watson supercomputer will be used by 10 US cancer centers to identify a
March 21, 2015
Concerns remain about the definition of a high risk population who can benefit from low-dose computed tomography screening programs.
March 12, 2015
Samples from tissue microarrays of 552 NSCLC patients were analyzed to measure the levels of 3 different tumor-infiltrating lymphocytes (TILs): CD3, CD8, and CD20. An elevated level of CD3 or CD8 was associated with longer survival.